In mouse xenograft models of FLT3-ITD mutant AML, Gilteritinib alone or ATO alone both reduced tumor size, while combination of Gilteritinib with ATO produced a profound treatment (Fig. 10a, b). The gene discussed is FLT3; the disease is acute myeloid leukemia.